抗纤缓急方治疗特发性肺纤维化急性加重患者多中心随机对照研究OA北大核心CSTPCD

Objective To observe the efficacy of Kangxian Huanji Decoction(KHD)in the treatment of acute exacerbation of idiopathic pulmonary fibrosis(AE-IPF)and its effects on C-reactive protein(CRP),monocyte chemoattractant protein-1(MCP-1),and transforming growth factor(TGF)-β1.Methods Totally 80 AE-IPF patients were randomly assigned to experimental group and control group,40 patients in each group.On the basis of health education and routine treatment with Western medicine,the experimental group was given the KHD,while the control group was given the KHD placebo.The treatment lasted for 4 weeks and the follow-up was 12 weeks.The treatment failure rate was calculated and in hospital time was recorded.The levels of CRP,MCP-1 and TGF-β1 before and after treatment were measured by enzyme-linked immunosorbent assay(ELISA).Results Three cases in experimental group and 4 cases in control group dropped out.The full analysis set was used.Compared with control group,treatment failure rate(5.0％vs.22.5％),in hospital time[(14.13±5.98)d vs.(17.43±7.42)d],and levels of CRP and MCP-1 after treatment decreased in experimental group(P＜0.05,P＜0.01).There was no significant differences in adverse events between the 2 groups(P＞0.05).Conclusion KHD could reduce the rate of treatment failure and shorten the length of in hospital time in AE-IPF patients,the mechanism may be related with relief inflammatory reactions by lowering the levels of CRP and MCP-1.